Literature DB >> 21106862

Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production.

Akira Uruno1, Ken Matsuda, Naoya Noguchi, Takeo Yoshikawa, Masataka Kudo, Fumitoshi Satoh, William E Rainey, Xiao-Gang Hui, Jun-ichi Akahira, Yasuhiro Nakamura, Hironobu Sasano, Hiroshi Okamoto, Sadayoshi Ito, Akira Sugawara.   

Abstract

Peroxisome proliferator-activated receptor-γ (PPARγ) is a nuclear receptor for the antidiabetic agent thiazolidinedione, which exerts various physiological activities, independent of lowering blood glucose. However, the role of PPARγ in aldosterone production has not been clarified. The objective of this study was to investigate the effect of PPARγ on aldosterone synthase gene (CYP11B2) expression and aldosterone production. Localization of PPARγ expression in normal adrenal cortex was determined by immunohistochemistry. Aldosterone production and CYP11B2 expression levels were determined using human adrenocortical carcinoma H295R cells. Pioglitazone suppressed angiotensin II-induced aldosterone secretion and CYP11B2 expression. PPARγ was expressed in zona glomerulosa in human normal adrenal gland. PPARγ overexpression enhanced pioglitazone-mediated CYP11B2 transrepression. The pioglitazone-mediated suppression of aldosterone secretion and CYP11B2 expression were canceled by PPARγ L466A/E469A mutant. Pioglitazone also suppressed potassium-mediated CYP11B2 induction, but not N6-2'-O-dibutyladenosine-3',5'-cyclic monophosphate stimulation. Rosiglitazone and GW1929 also suppressed CYP11B2 transactivation. Mutation analysis revealed that the Ad1/CRE element in CYP11B2 5'-flanking region was responsible for the pioglitazone-mediated transrepression. Pioglitazone suppressed ionomycin and a truncated constitutively active form Ca(2+)/calmodulin-dependent kinase I (CaMKI)-mediated CYP11B2 transcriptional activation. A CaMK inhibitor KN-93 attenuated pioglitazone-mediated CYP11B2 transrepression. PPARγ suppresses CYP11B2 expression and aldosterone secretion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21106862     DOI: 10.1677/JME-10-0088

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  20 in total

1.  PCP4: a regulator of aldosterone synthesis in human adrenocortical tissues.

Authors:  Saulo J A Felizola; Yasuhiro Nakamura; Yoshikiyo Ono; Kanako Kitamura; Kumi Kikuchi; Yoshiaki Onodera; Kazue Ise; Kei Takase; Akira Sugawara; Namita Hattangady; William E Rainey; Fumitoshi Satoh; Hironobu Sasano
Journal:  J Mol Endocrinol       Date:  2014-02-24       Impact factor: 5.098

Review 2.  Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair.

Authors:  Wei Cai; Tuo Yang; Huan Liu; Lijuan Han; Kai Zhang; Xiaoming Hu; Xuejing Zhang; Ke-Jie Yin; Yanqin Gao; Michael V L Bennett; Rehana K Leak; Jun Chen
Journal:  Prog Neurobiol       Date:  2017-10-12       Impact factor: 11.685

Review 3.  Human adrenocortical carcinoma cell lines.

Authors:  Tao Wang; William E Rainey
Journal:  Mol Cell Endocrinol       Date:  2011-09-05       Impact factor: 4.102

4.  Post mortem evaluation of inflammation, oxidative stress, and PPARγ activation in a nonhuman primate model of cardiac sympathetic neurodegeneration.

Authors:  Jeanette M Metzger; Helen N Matsoff; Alexandra D Zinnen; Rachel A Fleddermann; Viktoriya Bondarenko; Heather A Simmons; Andres Mejia; Colleen F Moore; Marina E Emborg
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240

5.  Crosstalk between peroxisome proliferator-activated receptor-γ and mineralcorticoid receptor in TNF-α activated renal tubular cell.

Authors:  Jing Xiao; Weijun Chen; Yijun Lu; Xiaoli Zhang; Chensheng Fu; Zhenwen Yan; Zhenxing Zhang; Zhibin Ye
Journal:  Inflamm Res       Date:  2015-06-14       Impact factor: 4.575

Review 6.  Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.

Authors:  David Della-Morte; Raffaele Palmirotta; Ashish K Rehni; Donatella Pastore; Barbara Capuani; Francesca Pacifici; Maria Laura De Marchis; Kunjan R Dave; Alfonso Bellia; Giuseppe Fogliame; Patrizia Ferroni; Giulia Donadel; Francesco Cacciatore; Pasquale Abete; Chuanhui Dong; Antonello Pileggi; Mario Roselli; Camillo Ricordi; Paolo Sbraccia; Fiorella Guadagni; Tatjana Rundek; Davide Lauro
Journal:  Pharmacogenomics       Date:  2014-12       Impact factor: 2.533

7.  Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.

Authors:  Bradley A Maron; Ying-Yi Zhang; Kevin White; Stephen Y Chan; Diane E Handy; Christopher E Mahoney; Joseph Loscalzo; Jane A Leopold
Journal:  Circulation       Date:  2012-07-11       Impact factor: 29.690

8.  The Keap1-Nrf2 system prevents onset of diabetes mellitus.

Authors:  Akira Uruno; Yuki Furusawa; Yoko Yagishita; Toshiaki Fukutomi; Hiroyuki Muramatsu; Takaaki Negishi; Akira Sugawara; Thomas W Kensler; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2013-05-28       Impact factor: 4.272

Review 9.  Aldosterone and cardiovascular disease: the heart of the matter.

Authors:  B Julie He; Mark E Anderson
Journal:  Trends Endocrinol Metab       Date:  2012-10-03       Impact factor: 12.015

10.  The effect of pioglitazone on aldosterone and cortisol production in HAC15 human adrenocortical carcinoma cells.

Authors:  Zhi-qiang Pan; Ding Xie; Vivek Choudhary; Mutsa Seremwe; Ying-Ying Tsai; Lawrence Olala; Xunsheng Chen; Wendy B Bollag
Journal:  Mol Cell Endocrinol       Date:  2014-07-17       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.